[doptabs]
[doptab title=”Overview”]

Florida Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Florida

Florida Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Florida Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Florida Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

[/doptab]
[doptab title=”Treatment and Research”]

Research

[dopaccordions]
[dopaccordion title=”Sachdeva, Nandip S. Biodegradable Nanocapules For Delivery Of Monensin As Potentiator Of Immunotoxins Grant: 2S06GM008111-250048″ icon=27 activeicon=28]

Abstract: Immunotoxins have been used as tumor-specific cytotoxic agents by various investigators in academics and industry. One of the major limitations has been their low potency in vivo. Potentiators like monensin have been used with great success in vitro but their lipophillic nature has precluded their use in vivo. Liposomes (with long circulating times) containing monensin are being currently investigated as potentiators of immunotoxins in vitro and in vivo. The main objective of this research is to prepare nanocapsules of a carboxylic ionophore, monensin which can bypass the reticuloendothelial system (to be termed as ‘stealth nanocapsules’). These nanocapsules will be used as potentiators of the anti My9 immunotoxin conjugate (IT) which is presently in Phase III clinical trials. The nanocapsules will be fully characterized for their entrapment efficiency, size, stability and pharmacokinetics profile. Stealth monensin nanocapsules will be incubated with the IT conjugate and different human tumor cell lines to see the in vitro potentiation. All in vitro qualitative and quantitative parameters of monensin nanocapsules will be compared to ‘stealth’ monensin liposomes. Monensin nanocapsules will be further tested for their potentiation of IT in vivo using human tumor xenografts in a i.p/i.v. and i.v./i.v. tumor model (using nude mice) with stealth monensin liposomes as controls. Two different human tumors, H- mesothelioma and HL-60 cells will be used as tumor xenografts. The results emanating from the above studies will allow us to decide what drug delivery system to use, polymer based or lipid based. The completion of the above studies will allow us to choose one formulation for Phase I studies to be used in combination with the IT conjugate as a potentiator.

Tags: Drug Delivery System, Drug Design /synthesis /production, Drug Screening /evaluation, Immunotoxicity, Microcapsule, Monensin, Neoplasm /cancer Chemotherapy, Neoplastic Cell Antineoplastic, Pharmacokinetics Athymic Mouse, Calorimetry, Computer Processing Of Laboratory Data, High Performance Liquid Chromatography, Human Tissue, Laboratory Mouse, Scanning Electron Microscopy, Statistics /biometry, Tissue /cell Culture

  • Followup Grant: 5S06GM008111-260048
  • Followup Grant: 3S06GM008111-26S10048
  • Followup Grant: 5S06GM008111-270048
  • Followup Grant: 3S06GM008111-27S10048
  • Followup Grant: 5S06GM008111-280048

[/dopaccordion]
[/dopaccordions]

Clinical Trials

[dopaccordions]
[dopaccordion title=”Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma

Intervention: Drug: vatalanib

More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Sorafenib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gefitinib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma Pancreatic Cancer; Sarcoma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Capecitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Pazopanib in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]

[dopaccordion title=”Active, not recruiting AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

[/dopaccordion]
[dopaccordion title=”Completed Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: Pemetrexed; Drug: Gemcitabine
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Alanosine in Treating Patients With Cancer” icon=27 activeicon=28]

Condition: Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Sarcoma
Intervention: Drug: L-alanosine
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Drug: Carboplatin, Bevacizumab and Pemetrexed
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.” icon=27 activeicon=28]

Condition: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Collecting Tumor Samples From Patients With Gynecological Tumors” icon=27 activeicon=28]

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Phase I Study of OSI-930 and Erlotinib in Cancer Tumors” icon=27 activeicon=28]

Condition: Advanced Solid Tumors
Intervention: Drug: OSI-930 and erlotinib
More Information

[/dopaccordion]
[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]

Hospitals and Cancer Centers

Physicians

Lary A. Robinson, M.D.
H. Lee Moffitt Cancer Center & Research Institute
At The University of South Florida
12902 Magnolia Dr.
Tampa, FL 33612

[/doptab]
[doptab title=”Cases”]

Owens-Corning Fiberglas Corp. v. Ballard
No. 92,963 , SUPREME COURT OF FLORIDA, August 26, 1999, Decided

Williams v. Am. Optical Corp.
Nos. 4D07-143, 4D07-144, 4D07-145, 4D07-146, 4D07-147, 4D07-148, 4D07-149, 4D07-150, 4D07-151, 4D07-153, 4D07-154, 4D07-405, And 4D07-407., COURT OF APPEAL OF FLORIDA, FOURTH DISTRICT, May 28, 2008, Decided

Fernandez v. Union Carbide Corp.
CASE NO. 3D03-3142 , COURT OF APPEAL OF FLORIDA, THIRD DISTRICT, September 6, 2006, Opinion Filed

Greene v. Csx Transp.
1010357 , SUPREME COURT OF ALABAMA, August 30, 2002, Released

[/doptab]
[doptab title=”Lawyers”]

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.

[/doptab]
[/doptabs]